Title
A study evaluating the safety and efficacy of anti-CD19 CAR T in subjects with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

Topic
A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.

Number of Participants
50 subjects

Study Design
Corsano will deliver CardioWatch 287-2 with CellPoint branded version of Corsano Trials to interact with CellPoint trial patients and to simplify the way patient data is collected and processed (answers to questions, vital signs, etc.). The App will facilitate interaction with patients.

Inclusion Criteria
Signed informed consent form
2. Age ≥ 18 years
Histologically confirmed diagnosis of CD19+ CLL or SLL with an indication for therapy according to iwCLL criteria, Richter’s transformation is allowed
Documented relapsed or refractory disease after at least 2 prior lines of therapy:
• Subjects must have been exposed to Bruton tyrosine kinase (BTK)-inhibitors (e.g. ibrutinib, acalabrutinib)
• Richter’s patients who failed a BTK-inhibitor are eligible regardless of number of prior lines of therapy received
Measurable disease according to iwCLL
ECOG performance status of 0 or 1
Adequate bone marrow function defined as:
• Absolute neutrophil count (ANC) ≥ 500/μL or ≥ 0.5 × 109/L (without G-CSF support within 7 days of the laboratory test or pegylated G-CSF support within 14 days of the laboratory test)
• Platelet count ≥ 50.000/μL or ≥ 50 x 109/L (without prior platelet transfusion within 7 days before the laboratory test)
• Absolute lymphocyte count ≥ 300/μL or ≥ 0.3 × 109/L;
• CD3+ count ≥ 150/μL or ≥ 0.15 × 109/L
Adequate renal, hepatic and pulmonary function defined as:
• Serum albumin ≥ 3.4 g/dL
• Creatinine clearance (Cockcroft Gault) ≥ 30 mL/min
• Aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)
• Alanine aminotransferase (ALT) ≤ 3 × ULN
• Total bilirubin ≤ 2 x ULN, except in subjects with Gilbert’s syndrome
• No clinically significant pleural effusion
• Baseline oxygen saturation > 92% on room air
Women of childbearing potential must have a negative serum pregnancy test at screening and prior to the first dose of cyclophosphamide and fludarabine
Women of childbearing potential and all male subjects must agree to use highly effective methods of contraception (failure rate of < 1% per year when used consistently and correctly) and agree to remain on a highly effective method of contraception from the time of signing the informed consent form until at least 6 months after BCN-CP01 infusion. Subjects must agree to not donate eggs or sperm during this period.

Exclusion Criteria
1. Prior treatment:
• Any anti-CD19 targeted therapy
• Salvage systemic therapy within 2 weeks or 5 half-lives (whichever is shorter) prior to leukapheresis
• Allogeneic stem cell transplant within 6 months before leukapheresis. Subjects who received an allogeneic transplant must have stopped all immunosuppressive medications for 6 weeks without signs of graft-versus-host disease. Subjects with active significant (overall Grade ≥ II, Seattle criteria) active graft-versus-host disease (GVHD) or moderate/ severe chronic GVHD (NIH consensus criteria) requiring systemic steroids are excluded.
• Corticosteroid therapy at a pharmacologic dose (> 10 mg/day of prednisone or equivalent doses of other corticosteroids) and other immunosuppressive drugs are not allowed for 7 days prior to leukapheresis and > 72 hours prior to BCN-CP01 infusion (if restarted)
2. History of malignancy other than lymphoma, except:
a. non-melanoma skin cancer
b. Carcinoma in situ (e.g. skin, cervix, bladder, breast) and disease free for at least 3 years prior to screening
c. Superficial bladder cancer
d. Asymptomatic low-grade or curatively treated localized prostate cancer for which watch-and-wait approach is standard of care
e. Any other cancer that has been in remission for ≥3 years prior to enrollment
3. History of BTK-associated side effects (e.g. symptomatic atrial fibrillation) or co-morbidities (e.g. oral anticoagulation use , severe hemophilia, or von Willebrand’s disease, etc.) that would prevent the patient from taking ibrutinib during the screening phase
4. Contraindication for Fludarabine or Cyclophosphamide
5. Known allergy or hypersensitivity to tocilizumab
6. Toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less
7. Active CNS involvement (with neurological changes) by disease under study, except if the CNS involvement has been effectively treated (i.e. patient is asymptomatic) and local treatment was > 4 weeks before screening
8. Clinically significant cardiac disease within 12 months of screening such as:
• Impaired cardiac function (LVEF < 45%) as assessed by echocardiogram performed ≤ 4 weeks prior to screening
• Evidence of pericardial effusion as determined by echocardiogram
• New York Heart Association Class III or IV congestive heart failure
• Clinically significant arrhythmias
9. Primary immunodeficiency
10. Stroke or seizure within 6 months of screening
11. History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within 2 years prior to screening
12. Infection with HIV, hepatitis B or hepatitis C virus. A history of hepatitis B or C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.
13. Uncontrolled infection or infection requiring antimicrobials for management, at screening
14. Vaccinated with live attenuated vaccine ≤ 4 weeks prior to leukapheresis
15. Pregnant or nursing women, or planning to become pregnant within 6 months after BCN-CP01 infusion
16. No major surgery ≤2 weeks prior to leukapheresis
17. In the investigator’s judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation

Study Centre
Major Pharma Client (NL)

Start time, Duration
February 2022, 36 months